Analysis
35 In my view, by diverting Cellos' opportunity for it to issue new shares into the market, Mr Huber improperly gained profits. The Scheme's essential elements as found by me were as follows. Between 20 September 2011 and 12 August 2015, at least 47,529,484 shares in CellOS were transferred to the Huber controlled entities from third party investors; my earlier reasons had a figure of 47,872,063 although this has now been revised down in the light of Ms Hennessy's further evidence. Mr Huber then promoted CellOS shares to investors, ostensibly to raise capital directly for CellOS by the issue of new shares. Between 20 September 2011 and 11 August 2015, Mr Huber sold via the Huber controlled entities at least 51,945,132 shares he had acquired from early investors to 355 third party investors. Those sales generated significant profits, which were in part directed to CellOS and attributed to LGA under the LGA loan agreement and later to Pized under the Pized loan agreement. Mr Huber's position is that he made no profit from the Scheme. Further details of the Scheme are set out in my principal reasons.
36 Let me first deal with Ms Hennessy's evidence as set out in the further Hennessy report and as debated at the hearing of this second stage.
37 Ms Hennessy was instructed by reference to my principal reasons to calculate the profit made by the respondents. She did so after making some revisions to some of the figures referred to in my reasons that the parties now accept. In the further Hennessy report, Ms Hennessy estimated that the profit made by the respondents on the sale of the shares was between AU$52,515,488 (the low scenario) and AU$114,196,498 (the high scenario), with a mid-point estimate of AU$105,477,847 (the mid scenario). These figures have been more recently updated, a matter which I will discuss later.
38 The difference between the two assessments of gross share sale proceeds caused the ultimate difference between the low scenario and mid scenario assessments of net profit. The difference was as a result of the assumptions adopted by Ms Hennessy as to the price paid to the respondents for the share sales where the sale price was not known. In both scenarios, Ms Hennessy relied upon the actual price paid for the shares where it was known. But in the low scenario in relation to the balance of share sales where the consideration was not known, Ms Hennessy assumed that the shares were sold at AU$2.23 per share, which was the weighted average AUD equivalent per share purchase price paid by the respondents for CellOS shares where the consideration was known. In the mid scenario, Ms Hennessy assumed that the shares were sold at AU$3.36 per share, which was in turn based on an assumed market for CellOS shares of US$2 per share pre-30 May 2014, and US$10 per share post-30 May 2014. The latter assessment was based on an analysis of the market price paid for CellOS shares, which showed that the typical price for CellOS shares was US$2 up to 30 May 2014, and US$10 thereafter. I found that in the period from September 2013 to July 2014, there were willing buyers of CellOS shares at US$5 and up to US$10. There was additional evidence before me that the market price for CellOS shares from mid-2014 was between US$5 and US$10. In the high scenario, further to the mid scenario, Ms Hennessy relied on a market price of US$5 for CellOS shares from 16 December 2013 to 30 May 2014.
39 It is worth stating now that adopting a conservative approach, which is in favour of the respondents, my final calculations rely upon relevant low scenario assumptions.
40 More generally, in my view, subject to some matters that I will discuss later, Ms Hennessy's methodological approach to the calculation of profit was appropriate.
41 Ms Hennessy also made an allowance for a substantial AU$1 million a year salary for Mr Huber, notwithstanding that it was for Mr Huber to make out any appropriate allowances in light of his conduct.
42 Now although Mr Huber was directed to file an affidavit disclosing the profits made by him, Mr Huber's affidavits in the main simply seek to challenge my principal reasons. Much remains unexplained and undisclosed, including Mr Huber's failure to disclose additional bank accounts which may show the flow of funds to him, the source of the payment of US$900,000 for the balance of his personal property purchase in Dubai or much in the way of corroborating documentation for the assertions contained in his affidavits.
43 In such circumstances, I am entitled to draw inferences about the respondents' profits extrapolating out from the known purchase and sales consideration, and upon making the assumption that shares were sold at market price. Indeed, it was for Mr Huber to prove that the consideration actually paid in respect of any of those share transfers was less than the market price, and to make out any appropriate deductable allowances.
44 Further, even if I do not accept Ms Hennessy's approach to the calculation of profit, my findings would support an order that the respondents profited by at least AU$30 million on an alternate basis. Let me explain.
45 AU$26,160,460 was paid to CellOS and attributed to the LGA loan agreement. I found that SG$16.8 million of that amount was derived from the sale of shares held by Basalt, which purchased its shares from early investors, and that "it [was] likely that the remainder derived from the sale of shares listed in sch 1 to the 5FASOC" (at [683] and [740]). I found that Mr Huber was not selling his personal shares in Blue Delorite, and had no other way of personally generating funds. To the extent there is any doubt, I accept that all funds attributable to the LGA loan agreement were net profits earned by Mr Huber from the sale of CellOS shares in the grey market. But on any view, at the least half the funds going into the LGA loan were derived from the Scheme.
46 Mr Huber then caused the conversion of the entire LGA loan agreement "debt" into 17,477,204 CellOS shares at SG$1.80 per share of which 16,815,157 were transferred on 9 May 2014 to Birinc (2,800,000), Sky Wealth (2,300,000), Rex Investors (1,681,516), Sun Way (2,350,000), Aura Finance (2,800,000), Harvest Sky (2,583,641) and Rich Max (2,300,000).
47 Further, as any profits improperly earned by Mr Huber were held on constructive trust for CellOS, the CellOS shares issued to LGA and their subsequent sale proceeds comprised the traceable property of CellOS. But on any view, over half of these shares were held on constructive trust for CellOS. Of the LGA shares, only 4,265,157 were sold for valuable consideration. On any view, these were held on trust for CellOS. Of these 4,265,157 shares, I made findings that 2,000,000 shares were sold to the Pecks for US$2 per share for a total consideration of US$4 million, 399,000 shares were sold to other investors for US$10 per share for a total consideration of US$3,990,000, and the consideration paid for the balance of the 1,866,157 shares was unknown.
48 Mr Huber stated that in the latter half of 2014, he sold about 1 million CellOS shares at US$10 per share. This is consistent with the evidence about the market price of CellOS shares at that time. If the balance of 1,866,157 shares where the consideration was unknown were sold at US$10 per share, then the total consideration for those shares was US$18,661,570. The total consideration, together with the known consideration paid for the LGA shares, would be US$26,651,570. Allowing a deduction for 10% brokerage fees would make a profit of US$23,986,413, or approximately AU$35,499,891.25 at exchange rates at the relevant time. Allowing a further deduction for salary for Mr Huber at AU$3,898,630, would mean a profit of AU$31,601,261.25.
49 I do not propose to elaborate further on this alternative basis as I have accepted Ms Hennessy's final calculations based upon her central methodology which I will explain later, albeit on the low scenario basis.
50 Let me at this point say something on the question of loss from the perspective of CellOS, even though I do not propose to award equitable compensation.
51 Ms Hennessy also estimated CellOS' loss at between AU$58,491,271 and AU$120,172,281, with a mid scenario assessment of AU$111,453,630.
52 By the Scheme, Mr Huber caused CellOS detriment by denying it the opportunity to raise funds by directly issuing shares to investors. Ms Hennessy's calculation of CellOS' loss differs only from her calculation of Mr Huber's profit in the sense that CellOS would not have had to acquire CellOS shares from early investors to resell. Accordingly there is no deduction for the estimated AU$9,874,413 paid by Mr Huber to acquire shares from early investors, nor any deduction for 10% in brokerage fees in relation to the purchase of those shares. Rather, Ms Hennessy assumed a AU$1 million per annum (AU$3,898,630 in total) cost to CellOS to issue the shares directly to investors.
53 The relevant but for analysis assumes that CellOS would have been able to issue the same quantum of shares for the same amount it is estimated that Huber sold them for, less the additional cost to CellOS to issue new shares instead of trading extant stocks.
54 Further, I found that Mr Huber caused detriment to CellOS, being the difference between the amount actually raised (reflected in SG$1.80 per share under the LGA loan agreement and option) and the amount CellOS would have raised if the shares had been issued by CellOS to investors (at least US$2, and possibly US$5 per share). I found that by exercising the option to convert debt to equity at SG$1.80 per share, Mr Huber caused relative detriment to CellOS' shareholders by diluting their shareholdings in disadvantageous circumstances.
55 It would seem for the evidence that the loss suffered from those uncommercial share issues (excluding sales commissions) was in excess of US$10,179,489.26, using the market price of US$2 per share, that is, AU$15,065,644.10 using an appropriate exchange rate, calculated as follows:
Date Shares issued Issue price SG$ SG$: US$ at issue Issue price US$ MP at US$2 Loss at MP of US$2 MP at US$5 Loss at MP of US$5
a) 28.06.13 6,453,773 11,616,791 0.78375 9,104,659.95 12,907,546 3,802,886.05 32,268,865 23,164,205.05
b) 2.10.13 3,467,877 6,242,179 0.7966 4,972,519.79 6,935,754 1,963,234.21 17,339,385 12,366,865.21
c) 10.12.13 333,333 600,000 0.80037 480,222 666,666 186,444.00 1,666,665 1,186,443.00
d) 6.02.14 1,666,666 3,000,000 0.78413 2,352,390 3,333,332 980,942.00 8,333,330 5,980,940.00
e) 19.02.14 1,388,888 2,500,000 0.79084 1,977,100 2,777,776 800,676.00 6,944,440 4,967,340.00
f) 27.03.14 4,166,666 7,500,000 0.78507 5,888,025 8,333,332 2,445,307.00 20,833,330 14,945,305.00
Total: 17,477,203 31,458,970 24,774,916.74 34,954,406 10,179,489.26 87,386,015 62,611,098.26